iiinova — where your digital self keeps evolving

Delta4 @delta4ai.bsky.social · 29/09/2026

❤️𝐖𝐨𝐫𝐥𝐝 𝐇𝐞𝐚𝐫𝐭 𝐃𝐚𝐲 For a long time, cardiovascular disease, kidney disease, obesity and diabetes have been approached as separate problems. The emerging concept of 𝐜𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫–𝐤𝐢𝐝𝐧𝐞𝐲–𝐦𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐜 (𝐂𝐊𝐌) 𝐡𝐞𝐚𝐥𝐭𝐡 brings these systems together. For us at #Delta4, this systems-level perspective matters.

000

Delta4 @delta4ai.bsky.social · 25/09/2026

#PerMediK came to a close in Tallinn this September — but the collaborations it created continue. One example: Pauline, pediatric trainee & PhD student at UZ Ghent/Ghent University, presented our joint work on network-based modeling of inflammatory signatures in pediatric #CKD. #kidneyhealth

000

Delta4 @delta4ai.bsky.social · 22/09/2026

PhD candidates, supervisors and experts came together in Tallinn for scientific exchange — spanning CKD biomarkers, peptidomics, comp. approaches, personalized treatment and clinical decision-making. The PhD candidates return to the desk and lab benches — hopefully with new inspiration. 💙 #PICKED

000

Delta4 @delta4ai.bsky.social · 15/09/2026

𝐇𝐨𝐰 𝐝𝐨 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 𝐰𝐡𝐢𝐜𝐡 𝐬𝐮𝐦𝐦𝐚𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐦𝐞𝐭𝐡𝐨𝐝 𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐰𝐨𝐫𝐤𝐬 𝐛𝐞𝐬𝐭 𝐟𝐨𝐫 𝐛𝐢𝐨𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐥𝐢𝐭𝐞𝐫𝐚𝐭𝐮𝐫𝐞? We put 62 summarization methods to the test on 1,000 biomedical abstracts. 𝑻𝒉𝒆 𝒓𝒆𝒔𝒖𝒍𝒕𝒔 𝒘𝒆𝒓𝒆 𝒏𝒐𝒕 𝒒𝒖𝒊𝒕𝒆 𝒘𝒉𝒂𝒕 𝒘𝒆 𝒆𝒙𝒑𝒆𝒄𝒕𝒆𝒅. ➡️ Read the blog: lnkd.in/gZtVxPDv 📝 View the publication: lnkd.in/gj2NrN7A

000

Delta4 @delta4ai.bsky.social · 07/09/2026

Last year, we swapped laptops for lawn chairs. This year, we needed more lawn chairs than ever. 😄 There were more of us to fill them at our biggest Delta4 BBQ yet! Good food, good company, and a well-earned afternoon away from our screens. ☀️🌭 #Delta4 #TeamDelta4 #SummerBBQ

010

Delta4 @delta4ai.bsky.social · 31/08/2026

The volume of biomedical information is growing fast. But information alone isn't knowledge. Within Hyper-C, our LLM-RAG pipeline helps extract and structure information from scientific literature, feeding it into a contextualized knowledge framework. LLMs as part of the Hyper-C infrastructure:

000

Delta4 @delta4ai.bsky.social · 25/08/2026

𝙎𝙐𝙈𝙈𝙀𝙍 𝙋𝘼𝙏𝙃𝙊𝙇𝙊𝙂𝙄𝙀𝙎. A small 𝘱𝘩𝘰𝘵𝘰𝘨𝘳𝘢𝘱𝘩𝘪𝘤 𝘴𝘵𝘶𝘥𝘺 in Vergänglichkeit, courtesy of the Vienna summer and an increasingly existential office plant. It did not make a full recovery. It left the building. #SummerPathologies #Plantlife #Biology #Office

010

Delta4 @delta4ai.bsky.social · 18/08/2026

What is it like to work with Delta4? Across nephrology, oncology, neuroimmunology & beyond, our partners highlight scientific rigor, computational expertise and our ability to turn complex biomedical data into actionable insights. See what others say: delta4.ai/services/ #DrugDiscovery

020

Delta4 @delta4ai.bsky.social · 14/08/2026

Why can sunlight help psoriasis? Moderate UVB exposure can slow excessive skin cell growth and reduce inflammation by influencing key immune pathways. Understanding these mechanisms helped shape today's targeted biologic therapies. #PsoriasisActionMonth

010

Delta4 @delta4ai.bsky.social · 10/08/2026

Delta4’s AI drug discovery engine is available directly on a global life science marketplace, making it easier for pharma and biotech teams to explore new indications and drug repositioning opportunities with Hyper‑C. 🔗 Discover more in a blog by Scientist.com: www.scientist.com/blog/acceler...

020

Delta4 @delta4ai.bsky.social · 04/08/2026

Finding the right #compounds for the right #diseases is a key challenge in #DrugRepositioning. Delta4’s Hyper-C platform starts with disease biology to identify promising therapeutic opportunities and provides mechanistic rationales to support development decisions. Read more: delta4.ai/services/

000

Delta4 @delta4ai.bsky.social · 29/07/2026

Many diseases require more than a single #therapeutic approach. With the support of #Combo-C, we identify and evaluate promising #DrugCombinations, providing the biological rationale behind each prediction—helping pharma prioritize candidates before the lab. Explore: delta4.ai/services/ #Delta4

010

Delta4 @delta4ai.bsky.social · 23/07/2026

Sjögren's syndrome is often described as a disease of dry eyes and dry mouth. But the reality is far more complex. Around 90% of people diagnosed with Sjögren's are women, and many symptoms overlap with perimenopause and menopause, contributing to delayed recognition and diagnosis. #SjogrensDay

041

Delta4 @delta4ai.bsky.social · 16/07/2026

#SyntheticLethality is not only about new targets — it’s about treating the right patients in the right way. With Hyper-C, Delta4 connects multi-omics data to prioritize synthetic lethal interactions and enable smarter patient selection and trial design. Read more: 🔗 delta4.ai/synthetic-lethality

000

Delta4 @delta4ai.bsky.social · 10/07/2026

Chronic diseases aren’t just “organ problems.” Nearly 1 in 3 adults lives with multiple chronic conditions, driven by shared systemic processes. A systems biology view helps us find new levers for resilience and shows that biology is not static, but open to positive influence. #ChronicDiseaseDay

030

Delta4 @delta4ai.bsky.social · 06/07/2026

#CKD research is moving fast, but translation into practice still lags. The KidneyHealth #COST Action CA25128 (starting Sept) builds a Europe-wide network to bridge that gap. D4's Computational Biology Lead represents Austria on the Mgmt Committee. Join the effort! www.cost.eu/actions/CA25...

010

Delta4 @delta4ai.bsky.social · 01/07/2026

#DISCOVER-ME has officially launched! The first #HorizonEurope project dedicated to ME/CFS brings together 20 international partner institutions & leading experts in ME/CFS and Post-Acute Infection Syndromes (#PAIS). One of the goals: pave the way for targeted treatment strategies. #MECFS

050

Delta4 @delta4ai.bsky.social · 22/06/2026

Diseases are rarely driven by a single pathway. Drugs rarely act on a single mechanism. By integrating diverse biological data into a unified framework, the Hyper-C platform helps identify connections that may otherwise remain hidden. Explore: delta4.ai/hyper-c/ #DrugDiscovery #AI #SystemsBiology

010

Delta4 @delta4ai.bsky.social · 16/06/2026

#Synthetic lethality is a promising concept in precision oncology, but discovery remains the bottleneck. With ~20,000 genes, the number of possible interactions is enormous. Most remain unmapped, but computational approaches can help narrow the space. ➡️https://delta4.ai/synthetic-lethality #Oncology

010

Delta4 @delta4ai.bsky.social · 14/06/2026

Most people know their blood type because it matters for transfusions during emergencies. But ABO blood groups influence clotting, interactions with pathogens, and even susceptibility to certain diseases. Your blood type may modify risk—but it doesn't determine your future. #WorldBloodDonorDay

010

Delta4 @delta4ai.bsky.social · 06/06/2026

Austria's life science ecosystem continues to grow and innovate. We're excited to join Austrian Life Science Day on June 16th to connect with researchers, biotech innovators, and industry partners from across the community. Let's meet there! #AustrianLifeScienceDay #LifeSciences #Biotech

010

Delta4 @delta4ai.bsky.social · 30/05/2026

MS is increasingly understood as more than an autoimmune disease. 💡 Neuroinflammation, glial cells, neurodegeneration, and tissue repair interact in highly complex ways. Progress will come from understanding these systems and their interplay. #WorldMSDay #MultipleSclerosis #Neuroinflammation

010

Delta4 @delta4ai.bsky.social · 22/05/2026

The FDA is encouraging drug repurposing—finding new uses for existing drugs in areas of unmet need. At Delta4, we extend this to drug combinations, aiming to identify synergistic, multi-target strategies for complex diseases. #DrugRepurposing #SystemsBiology #PrecisionMedicine

010

Delta4 @delta4ai.bsky.social · 18/05/2026

#Delta4's Enrico presented his poster at the #YSA Symposium 2026 at the Medical University of Vienna. His work on systems-biological modeling of the #AKI-to-#CKD transition was selected for Session V (Regeneration & Transplantation) and sparked lively scientific discussion. #TranslationalResearch

021

Delta4 @delta4ai.bsky.social · 12/05/2026

ME/CFS is complex, multi-system, and still poorly understood. Multiple ongoing research efforts aim to decode its biology, enabling better diagnosis and targeted treatments. Progress starts with understanding complex disease, and AI-supported target discovery is one piece of that puzzle. #MECFS

120

Delta4 @delta4ai.bsky.social · 08/05/2026

Ovarian cancer is not just about earlier detection—it’s about complex biology. Heterogeneity and resistance limit one-size-fits-all treatment. Progress will come from understanding mechanisms, not just identifying disease. #WorldOvarianCancerDay #Oncology #PrecisionMedicine

010

Delta4 @delta4ai.bsky.social · 30/04/2026

Stress isn’t just lifestyle—it triggers real biological cascades: #inflammation, #hormonal imbalance, #tissue damage. Over time, this drives disease. Managing stress is a long-term investment in your bodily health. #BeTheChange #SystemsBiology #Relax #StressAwareness #ChronicStress

010

Delta4 @delta4ai.bsky.social · 28/04/2026

Diseases like #ADPKD and #FSGS are driven by complex, interconnected biological networks. What if the key to better therapies lies not in one target — but in understanding the system? At Delta4, we advocate for a shift towards network-based approaches in #drugDiscovery. #systemsbiology #techbio

010

Delta4 @delta4ai.bsky.social · 21/04/2026

Delta4 will be represented at #Bio€quity Europe in Prague by Josef Thalmann, who will be on-site for investor meetings and collaboration discussions in the field of data-driven drug repositioning and indication expansion. If you plan to attend, feel free to reach out and schedule a conversation!

010

Delta4 @delta4ai.bsky.social · 19/04/2026

WORLD #LIVER DAY: Liver safety and liver disease aren’t separate problems. Cases like #Ontozry show risks still emerge post-approval, while PBC/PSC reflect immune-driven damage. Different triggers—same system under stress. Read more on #Delta4's work in #PBC/#PSC: delta4.ai/development-...

010

Delta4 @delta4ai.bsky.social · 17/04/2026

In proof-of-concept clinical trials, mechanism matters more than magnitude. Targeted #biomarkers and multi-#omics approaches help researchers to: 🧬Confirm #target engagement, 🧬Identify #responder subgroups, 🧬Reduce noise in small #cohorts. Read more: delta4.ai/proof-of-con...

010

Delta4 @delta4ai.bsky.social · 15/04/2026

💡 #Collagen fragments in urine can predict #mortality across ICU and non-ICU populations (#Proteomics). Not a single biomarker, but a systemic readout of #tissue integrity and structural change. Read more on this non-invasive signal in the following study: doi.org/10.1002/pmic... #BiomarkerResearch

010

Delta4 @delta4ai.bsky.social · 09/04/2026

At Delta4, our commitment to the rare disease community is grounded in both compassion and rigorous data science. Together, we are transforming awareness into meaningful action—supporting innovation and hope for everyone affected by rare diseases. 💙💪 #Delta4 #RareDisease #Innovation

010

Delta4 @delta4ai.bsky.social · 07/04/2026

Better health won’t come from fitting patients into models, but from understanding when they don’t fit. AI is great at finding patterns — but biology doesn’t always follow them. Rare diseases, individual variability, and context need smarter approaches. #WorldHealthDay #TogetherForScience

010

Delta4 @delta4ai.bsky.social · 02/04/2026

💡 Most drug discovery tools look at biology in segments. Hyper-C is built to see diseases and drugs play out across systems. Explore Hyper-C's core components at 📍 delta4.ai/hyper-c #DrugDiscovery #SystemsBiology #Biotech #TargetDiscovery #BiomarkerID #indicationExpansion

020

Reposted by Delta4

PICKED Project @projectpicked.bsky.social · 31/03/2026

Great discussions at the #PICKED webseminars 👏 9 DC presentations, strong supervisor feedback, and real cross-project exchange. More: www.projectpicked.eu/news-and-eve... Next up: Tallinn (15–16 Sept) #HorizonEU #MSCA #RareDiseases

041

Delta4 @delta4ai.bsky.social · 30/03/2026

#PerMediK’s 8th Meeting marked the start of its final year. A strong network driving collaboration in personalised medicine for #CKD — now facing the key task of aligning scientific exchange with real-world impact. Great to have Paul & Kinga from Delta4 on site, exchanging ideas and experience.

020

Delta4 @delta4ai.bsky.social · 21/03/2026

💡What if the next #KidneyDisease therapy is already in your pipeline? By leveraging in-silico modeling and network biology, we can: ✔ Identify new targets ✔ Reveal biomarkers ✔ Expand indications for existing assets ✔ De-risk development early. Let's rethink kidney disease as an #opportunity.

010

Delta4 @delta4ai.bsky.social · 17/03/2026

Kidney disease highlights both the promise and the challenge of PoC clinical trials. Slow disease progression and heterogeneous biology make traditional endpoints impractical in early studies. 🧬Explore more: delta4.ai/proof-of-con...

011

Delta4 @delta4ai.bsky.social · 12/03/2026

🌍 #Kidney disease often starts quietly — sometimes with small, seemingly unrelated changes in routine lab results. We believe that understanding connections across pathways and systems is key to uncovering new therapeutic strategies. Let's look beyond individual data points & find new approaches.

010

Delta4 @delta4ai.bsky.social · 09/03/2026

🪢Seeing connections changes decisions. Our new Services page features an interactive map of Delta4’s expertise. Connecting the dots is our specialty. Now you can explore the many dimensions of drug and biomarker discovery at your own pace. 💡Learn more: delta4.ai/services #Delta4 #DrugDiscovery

010

Delta4 @delta4ai.bsky.social · 08/03/2026

On today's International Women's Day, we celebrate the #women shaping #science, and the progress still lying ahead. 💡Biological sex differences profoundly affect disease mechanisms, drug metabolism, and treatment response. Closing these gaps is essential for safer and more effective therapies.

010

Delta4 @delta4ai.bsky.social · 04/03/2026

💡 Endometriosis is not just a local disease & is increasingly understood as a systemic, neuroimmunological condition. During Endometriosis Awareness Month, we invite partners to explore new, systems-level approaches — from biomarker identification to therapeutic hypotheses. Let’s connect! #EndoMarch

020

Delta4 @delta4ai.bsky.social · 28/02/2026

Rare Disease Day reminds us that behind every statistic is a story of resilience. Delta4 is committed to advancing data‑driven solutions that support clearer understanding and stronger outcomes for the rare disease community. 💙💪 #Delta4 #RareDiseaseDay #RareDiseases

020

Delta4 @delta4ai.bsky.social · 27/02/2026

Common challenges in proof of concept (PoC) studies: 🧬Patient heterogeneity 🧬Small sample sizes & weak signal detection 🧬Biomarkers that don’t align with drug mechanisms Learn how we tackle these 👇 delta4.ai/proof-of-con...

020

Delta4 @delta4ai.bsky.social · 23/02/2026

Ever wondered how Hyper-C works and what real-world impact it delivers? A new overview on our website features four success stories that highlight the strength of our “dream team”: systems biology, computational modeling, and deep biological expertise. Explore more: delta4.ai/success-stor...

010

Delta4 @delta4ai.bsky.social · 13/02/2026

PoC clinical trials are one of the most critical inflection points in drug development, answering the question: Does the drug work in humans the way it was intended to? When done poorly, PoC trials can prematurely eliminate promising therapies. 👉https://delta4.ai/proof-of-concept-clinical-trials/

010

Delta4 @delta4ai.bsky.social · 10/02/2026

At Delta4 we’re always looking for key partnerships that are mutually beneficial. Together, we can #accelerate progress and accomplish more 🤝 Connect with us to explore #collaboration opportunities! delta4.ai/partnering/ #Delta4

020

Delta4 @delta4ai.bsky.social · 06/02/2026

Discover the EMA’s 2025 highlights, including key repurposed and expanded medicines like Fabhalta, Mounjaro and Uplizna. Dive into the full overview: www.linkedin.com/posts/europe... #Delta4 #EMA

020

Delta4 @delta4ai.bsky.social · 02/02/2026

2025 was a landmark year for #semaglutide. Starting as a #diabetes and weight-management therapy, it has now expanded into kidney, liver, and cardiovascular disease — reflecting a broader shift toward mechanism-driven treatment strategies and showing the importance of indication expansion. #ozempic

010